Case Report
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Radiol. Jan 28, 2011; 3(1): 32-37
Published online Jan 28, 2011. doi: 10.4329/wjr.v3.i1.32
Breast and lung metastasis from pancreatic neuroendocrine carcinoma
Shevonne Satahoo-Dawes, Joshua Palmer, Eddie W Manning III, Joe Levi
Shevonne Satahoo-Dawes, Joshua Palmer, Eddie W Manning III, Joe Levi, DeWitt Daughtry Family Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL 33136, United States
Author contributions: Satahoo-Dawes S and Palmer J performed the literature search; Satahoo-Dawes S, Palmer J and Manning III EW analyzed the literature and wrote the manuscript; Levi J and Manning III EW performed the surgery, collected the photographs and coordinated the study.
Correspondence to: Eddie W Manning III, MD, DeWitt Daughtry Family Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL 33136, United States. emanning@med.miami.edu
Telephone: +1-305-5851280 Fax: +1-305-5856043
Received: March 31, 2010
Revised: December 7, 2010
Accepted: December 14, 2010
Published online: January 28, 2011
Abstract

Pancreatic neuroendocrine tumors (PNETs) are an uncommon malignancy, accounting for a small percentage of all pancreatic malignancies. Due to their insidious course, most PNETs present with metastatic disease. Although reports in the literature describe PNET metastasis to the liver, lung and brain, to date there are no reports of stage IV disease involving the breast. Moreover, the lack of consensus regarding classification and treatment of this entity leaves practitioners without standards of practice or a firm base from which to formulate prognosis. In this report, the case of a previously healthy 51-year-old woman with stage IV PNET is examined. After combined neoadjuvant therapy with 5-fluorouracil, carboplatin, etoposide and radiation, surgical resection revealed metastatic PNET to the breast and lung, with no microscopic evidence of residual disease within the pancreas. An extensive analysis of the presentation, diagnosis, imaging modalities, treatment options, and prognosis is included in the discussion. As demonstrated by our review, there is a need for further studies to delineate inconclusive evidence with respect to subtype classification, treatment and prognosis of PNETs.

Keywords: Neuroendocrine tumor; Metastatic tumor; Pancreatic tumor; Breast; Lung